作者
Jay H Traverse, Timothy D Henry, Stephen G Ellis, Carl J Pepine, James T Willerson, David XM Zhao, John R Forder, Barry J Byrne, Antonis K Hatzopoulos, Marc S Penn, Emerson C Perin, Kenneth W Baran, Jeffrey Chambers, Charles Lambert, Ganesh Raveendran, Daniel I Simon, Douglas E Vaughan, Lara M Simpson, Adrian P Gee, Doris A Taylor, Christopher R Cogle, James D Thomas, Guilherme V Silva, Beth C Jorgenson, Rachel E Olson, Sherry Bowman, Judy Francescon, Carrie Geither, Eileen Handberg, Deirdre X Smith, Sarah Baraniuk, Linda B Piller, Catalin Loghin, David Aguilar, Sara Richman, Claudia Zierold, Judy Bettencourt, Shelly L Sayre, Rachel W Vojvodic, Sonia I Skarlatos, David J Gordon, Ray F Ebert, Minjung Kwak, Lemuel A Moyé, Robert D Simari
发表日期
2011/11/16
期刊
Jama
卷号
306
期号
19
页码范围
2110-2119
出版商
American Medical Association
简介
Context
Clinical trial results suggest that intracoronary delivery of autologous bone marrow mononuclear cells (BMCs) may improve left ventricular (LV) function when administered within the first week following myocardial infarction (MI). However, because a substantial number of patients may not present for early cell delivery, the efficacy of autologous BMC delivery 2 to 3 weeks post-MI warrants investigation.
Objective
To determine if intracoronary delivery of autologous BMCs improves global and regional LV function when delivered 2 to 3 weeks following first MI.
Design, Setting, and Patients
A randomized, double-blind, placebo-controlled trial (LateTIME) of the National Heart, Lung, and Blood Institute–sponsored Cardiovascular Cell Therapy Research Network of 87 patients with significant LV dysfunction (LV ejection fraction [LVEF] ≤45%) following successful primary percutaneous coronary intervention (PCI …
学术搜索中的文章
JH Traverse, TD Henry, SG Ellis, CJ Pepine… - Jama, 2011